Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Flower in connection with the acquisition of the energy storage facility Bredhälla from OX2
Mandate

Vinge has advised Flower in connection with the acquisition of the energy storage facility Bredhälla from OX2.

June 11, 2024 M&A Banking and Finance Environmental Law Commercial Agreements Real Estate and Construction FDI

The energy storage facility Bredhälla consists of batteries utilizing lithium-ion technology with a total capacity of 42,5MW /42,5MWh spread across 20 modules, making it the largest battery park in Sweden. Bredhälla will provide ancillary services to Svenska Kraftnät to ensure stability in the electricity grid and participate in wholesale markets by providing energy arbitrage.

The acquisition strengthens Flower’s position as the leading battery optimizer in Sweden.

Vinges team mainly consisted of Peter Sundgren and Gustav Wahlberg (M&A), Albert Wållgren and Jolinn Uhlin (Financing), Johan Cederblad and Lina Österberg (Environment), Jolene Reimersson and Carl Lexenberg (Commercial Agreements), Daniel Prawitz and Clara Klingspor (Construction) as well as Daniel Wendelsson, Felizia Wiker, Dagne Sabockis and Alva Chambert (FDI).

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

 Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025